| # | Side effect | Count | Frequency |
|---|---|---|---|
| 0 | EOSINOPHILIC HEPATITIS | 1 | 0.2000 |
| 1 | LYMPHOCYTIC INFILTRATION | 1 | 0.0010 |
| 2 | MONOCYTE COUNT INCREASED | 1 | 0.0003 |
| 3 | ISCHAEMIA | 1 | 0.0002 |
| 4 | LACTIC ACIDOSIS | 6 | 0.0002 |
| 5 | GAMMA-GLUTAMYLTRANSFERASE INCREASED | 2 | 0.0001 |
| 6 | HEPATITIS C | 1 | 0.0001 |
| 7 | JAUNDICE | 2 | 0.0001 |
| 8 | HEPATOCELLULAR INJURY | 1 | 0.0001 |
| 9 | HEPATOTOXICITY | 1 | 0.0000 |
| 10 | BLOOD ALKALINE PHOSPHATASE INCREASED | 1 | 0.0000 |
| 11 | BLOOD BILIRUBIN INCREASED | 1 | 0.0000 |
| 12 | ACUTE KIDNEY INJURY | 5 | 0.0000 |
| 13 | DRUG INTERACTION | 5 | 0.0000 |
| 14 | TYPE 2 DIABETES MELLITUS | 1 | 0.0000 |
| 15 | RENAL FAILURE ACUTE | 1 | 0.0000 |
| 16 | ASPARTATE AMINOTRANSFERASE INCREASED | 1 | 0.0000 |
| 17 | ALANINE AMINOTRANSFERASE INCREASED | 1 | 0.0000 |
| 18 | INFLUENZA LIKE ILLNESS | 1 | 0.0000 |
| 19 | TREATMENT FAILURE | 1 | 0.0000 |
| 20 | ABDOMINAL DISTENSION | 1 | 0.0000 |
| 21 | GENERAL PHYSICAL HEALTH DETERIORATION | 1 | 0.0000 |
| 22 | DEPRESSION | 1 | 0.0000 |
| 23 | PRODUCT USE IN UNAPPROVED INDICATION | 1 | 0.0000 |
| 24 | VOMITING | 1 | 0.0000 |
| 25 | HEADACHE | 1 | 0.0000 |
| 26 | DIARRHOEA | 1 | 0.0000 |
| 27 | DRUG INEFFECTIVE | 1 | 0.0000 |